OR WAIT null SECS
September 10, 2019
The transaction is set to be completed in the fourth quarter of 2019.
September 04, 2019
The drug will improve the treatment and prevention of invasive fungal infections.
The drug displayed improvement in progression-free survival and increased the time patients lived without disease progression or death by a median of 18.9 months.
In a Phase III trial for advanced small-cell lung cancer, the investigational antibody drug conjugate, Rova-T (rovalpituzumab tesirine), did not demonstrate a survival benefit for patients taking it.
The company has received breakthrough therapy designation for its prophylactic respiratory syncytial virus vaccine candidate for treating adults aged 60 years or older.
Roche has extended its offering period for the purchase of Spark to provide US and UK regulatory authorities with additional time to complete their review of the acquisition.
Vertex will use the acquisition to develop cell-based treatments for type 1 diabetes.
September 03, 2019
Valo Therapeutics has acquired a technology from Helsinki University that is expected to broaden its approach and expand the capability of its cancer vaccines platform, PeptiCRAd.
Gerresheimer has announced it will be expanding its ClearJect product line of pre-fillable syringes with a new 2.25-mL cyclic olefin polymer (COP) staked in needle (SIN) syringe.
The new facility, located in Ness Ziona, Israel, will support clinical phage manufacturing and can be expanded in the future to support commercial-scale manufacturing.